Changing the class of NSAID in cases of hepatotoxicity.

Larbre, J. P.; Collet, Philippe; Ravault, A; Lejeune, E

doi:10.1136/ard.47.9.791

Cited by 11 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…. It is recommended that if an individual experiences a hepatic reaction, they should switch to a NSAID in another class, avoid combining different NSAIDs and avoid NSAIDs that have a higher prevalence of liver toxicity …”

Section: Principle Adverse Reactions Of Nsaidsmentioning

confidence: 99%

“…Individuals over the age of 60 with previous hepatic complications, autoimmune system and who are taking other drugs that induce hepatic toxicity are at the greatest risk of developing NSAID-derived hepatic complications.. [55,57,61] It is recommended that if an individual experiences a hepatic reaction, they should switch to a NSAID in another class, avoid combining different NSAIDs and avoid NSAIDs that have a higher prevalence of liver toxicity. [64,65]…”

Section: Renalmentioning

confidence: 99%

See 1 more Smart Citation

Osteoarthritis of the hand II: chemistry, pharmacokinetics and pharmacodynamics of naproxen, and clinical outcome studies

Leung

Rainsford

Kean

2014

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objective This article aims to review osteoarthritis of the hand and the role of the non-steroidal anti-inflammatory drug (NSAID) naproxen on its management. We discuss the chemical and pharmacological properties of naproxen and the NSAID class, with an emphasis on its mechanism and adverse reactions. In the context of part I of this paper in characterizing hand osteoarthritis (OA), we review clinical trials that have been conducted involving hand OA and naproxen. Key findings The therapeutic effect of NSAIDs stems from its role on inhibiting cyclo-oxygenase (COX)-1 or COX-2 enzyme activity in the body. These enzymes play a major role in maintaining several functions in the body and due NSAIDs' inhibitory effects; many principle adverse reactions occur with the use of NSAIDs such as: gastrointestinal tract issues, cardiovascular risks, renal, hepatic, central nervous system and cutaneous. Review of clinical trials involving naproxen and hand OA show that it is significantly more efficacious when compared with placebo. Summary These studies, along with the finding that naproxen is of least cardiovascular risk in the NSAID class, may show that it can be part of one of the approaches in managing the condition. It is important to note that the optimal NSAID to use varies for each individual. The finding that the use of naproxen leads to the smallest increase in cardiovascular risk appeals to those at-risk individuals who suffer from OA and require pharmacological treatment for relief.

show abstract

Section: Principle Adverse Reactions Of Nsaidsmentioning

confidence: 99%

Section: Renalmentioning

confidence: 99%

Osteoarthritis of the hand II: chemistry, pharmacokinetics and pharmacodynamics of naproxen, and clinical outcome studies

Leung

Rainsford

Kean

2014

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

“…Hepatitis induced by non-steroidal anti-inflammatory drugs Si, We read with interest the letter by Llorca et al entitled 'Changing the class of NSAID in cases of hepatotoxicity'. 1 We would like to draw attention to the incidence and clinical features of this side effect.…”

mentioning

confidence: 99%

Hepatitis induced by non-steroidal anti-inflammatory drugs.

Netter¹,

Castot²,

Larrey³

et al. 1989

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

up as a double blind, controlled endoscopy study comparing an ulcer healing agent with placebo. As can be seen from our paper1 the study described was in two parts, the first being a survey of patients routinely attending a rheumatology outpatient clinic and the second phase of the study consisting of a report of the effects of an ulcer healing agent on non-steroidal anti-inflammatory drug (NSAID) induced peptic ulceration with the NSAID continued throughout treatment. The discrepancy between the prevalence of peptic ulceration in our patient population compared with that described by Dr Roth could possibly be due to patient selection and the type of population studied. In our own study we showed that smoking was an important risk factor in the development of the peptic ulceration in the rheumatoid population and yet this is a variable which is not always taken into account in previously reported studies of the prevalence of peptic ulceration in rheumatic disease. We would entirely agree with Dr Roth's comments that separate terminology should be used for NSAID gastropathy as one of the problems of multicentre studies is the standardisation of the criteria for gastric ulceration and the grading of mucosal lesions in this group of patients. Whether rheumatoid arthritis itself may predispose to peptic ulceration is an open question, and further studies with large numbers of patients whose demographic characteristics are carefully standardised will be required to answer this.

show abstract

Prediction of organ system toxicity with antirheumatic drug therapy

Buchanan¹,

Brooks²

1991

Prognosis in the Rheumatic Diseases

View full text Add to dashboard Cite

Changing the class of NSAID in cases of hepatotoxicity.

Cited by 11 publications

References 3 publications

Osteoarthritis of the hand II: chemistry, pharmacokinetics and pharmacodynamics of naproxen, and clinical outcome studies

Osteoarthritis of the hand II: chemistry, pharmacokinetics and pharmacodynamics of naproxen, and clinical outcome studies

Hepatitis induced by non-steroidal anti-inflammatory drugs.

Prediction of organ system toxicity with antirheumatic drug therapy

Contact Info

Product

Resources

About